Zurcher Kantonalbank (Zurich Cantonalbank) Macrogenics Inc Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

  • $34.1 Billion
  • Q4 2024

A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Macrogenics Inc stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 1,707 shares of MGNX stock, worth $3,721. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,707
Previous 1,707 -0.0%
Holding current value
$3,721
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024
SELL
$3.0 - $5.55 $43,095 - $79,725
-14,365 Reduced 89.38%
1,707 $5,000
Q2 2024

Jul 29, 2024
BUY
$3.31 - $18.51 $39,918 - $223,230
12,060 Added 300.6%
16,072 $68,000
Q1 2024

Apr 25, 2024
BUY
$9.77 - $21.47 $19,686 - $43,262
2,015 Added 100.9%
4,012 $59,000
Q4 2023

Jan 30, 2024
SELL
$4.48 - $10.11 $1,133 - $2,557
-253 Reduced 11.24%
1,997 $19,000
Q3 2023

Oct 25, 2023
SELL
$4.48 - $6.19 $3,333 - $4,605
-744 Reduced 24.85%
2,250 $10,000
Q2 2023

Aug 07, 2023
SELL
$4.62 - $7.54 $3,672 - $5,994
-795 Reduced 20.98%
2,994 $16,000
Q1 2023

May 08, 2023
BUY
$4.82 - $7.24 $18,262 - $27,432
3,789 New
3,789 $27,000
Q2 2020

Jul 28, 2020
BUY
$5.2 - $29.12 $20,217 - $113,218
3,888 Added 155.89%
6,382 $178,000
Q4 2017

Jan 31, 2018
BUY
$16.19 - $20.3 $16,659 - $20,888
1,029 Added 70.24%
2,494 $47,000
Q3 2017

Nov 08, 2017
BUY
$15.52 - $18.94 $22,736 - $27,747
1,465
1,465 $27,000

Others Institutions Holding MGNX

# of Institutions
131
Shares Held
56M
Call Options Held
28.3K
Put Options Held
197K
View Full List

About MACROGENICS INC

MGNX Quotes by TradingView
  • Ticker MGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 61,458,800
  • Market Cap $134M
  • Description
  • MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...
More about MGNX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email